19th Ave New York, NY 95822, USA
Join Now

Prostate Cancer Group

Portfolio Item Prostate Cancer Group
CLINICAL RESEARCH

The development of new drugs and therapeutic strategies for advanced prostate cancer is the main objective of our Group. We combine clinical trials, molecular correlative studies, and mechanistic studies following a bench-to-bedside-and-back research approach.

We integrate multidisciplinary expertise spanning clinical research, cancer biology, genomics and transcriptomics, bioinformatics, liquid biopsy, and clinical data science to advance precision medicine for patients with prostate cancer. To support this effort, we have established a platform for collecting longitudinal biospecimens and data from patients with advanced prostate cancer. These samples allow us to study the evolving nature of the disease and generate patient-derived laboratory models, which we use to investigate new therapeutic strategies in the lab.

Our clinical trial portfolio spans the entire disease continuum, with a focus on early phase trials of new compounds and biology-driven therapeutic strategies. Investigator-initiated clinical studies are central to our research strategy, providing a platform for correlative studies. We currently serve as the central laboratory for two academic multi-center clinical trials and manage the sample repository for IRONMAN; an international initiative to build a large clinical and biospecimen database from patients with metastatic prostate cancer.

The main lines of research include: 1) understanding how prostate cancers adapt to systemic therapies, with a focus on the cell cycle and DNA damage response regulation; 2) developing novel tissue and liquid biopsy molecular characterization approaches for improved patient stratification; and 3) identifying prognostic and predictive biomarkers to guide more precise treatment decisions. To achieve these goals, we study in-vitro and in-vivo models, including patient-derived xenografts (PDX) from the patients participating in our clinical studies. We study genomics and transcriptomics of clinical biospecimens, with a focus on ctDNA and tumor-derived extracellular vesicles. Additionally, we leverage both in-house and publicly available clinic-genomic databases to advance precision cancer care.

We are also leading the HOPE-Prostate study, a collaborative project with the SOLTI Group and Spanish prostate cancer medical societies to empower patients to undergo molecular testing. As part of this initiative, over 200 patients from across Spain have enrolled in the study and provided data and biospecimens.

We are honored to receive funding support from the U.S. Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP), the Spanish Ministry of Health, CRIS Cancer Foundation, Asociación Española Contra el Cáncer – AECC (Spanish Association Against Cancer), FERO Foundation, Prostate Cancer Foundation and the ”la Caixa” Foundation. We also have joint projects with biotech and pharmaceutical industry partners for the development of novel therapeutic strategies.

To accelerate progress, we embrace team science. We actively participate in collaborations that pool resources and expertise across multiple research groups worldwide.

Joaquin Mateo
Group Leader
Biosketch

Research Lines

  • To understand why some treatments for prostate cancer only work in some patients and not in others, so we can offer each patient the best therapeutic option for their individual case.
  • To test and develop new therapeutic strategies for prostate cancer in clinical trials.
  • Study how prostate cancer adapts to therapy, with a focus on targeting emerging vulnerabilities to delay disease recurrence.
  • Investigate tumor heterogeneity in response to therapy in preclinical and patient-derived xenograft models (PDX), as well as by interrogating patient biopsies.
  • Develop new liquid biopsy tools that can be used to monitor tumor evolution.
  • Development of academic clinical trials to validate our laboratory results in the clinic and leveraging patient biopsies for correlative studies.

Team

Group Leader
Joaquin Mateo
Senior Researcher
Irene Casanova
Staff researcher
Gisela Mir
Medical oncologists
Pablo Cresta, Maria Dolores Fenor de la Maza
Post-Doctoral Fellows
Nicolás Anselmino, Richard Norris
Clinical Research Fellow
Francesca Zacchi
Predoctoral researchers
Julian Brandariz, Youhao Chen, Victor Esquefa, Andrei Salca, Roma Sunder
Technicians
Teresa Casals, Lara de Llobet, Laura Martinez, Mar More, Anna Oliveira
Clinical Data Curator
Haitham Alatoom
Clinical Research Coordinator
Maria del Mar Suanes, Erika Saenz
Research Nurse
Ana Maria Castañeira, Helena Palma
Bionformatician
Daniel Aguilar, Manuel Ramos

Publications

Most relevant scientific publications

  1. Arce-Gallego S, Esquefa V, Domenech H, Salca A, Aguilar D, Casals T, Mir G, Simonetti S, Oliveira A, de Llobet L, Neeb A, Brandariz J, Anselmino N, Casanova-Salas I, Herranz N, Serra V, de Bono JS, Mateo J. Combination therapy overcomes secondary PARPi resistance in ATM-deficient prostate cancer. NPJ Precis Oncol. 2025 Nov 26;9(1):407.
  2. Brandariz J, de Llobet L, Esquefa V, Aguilar D, Salca A, Arce-Gallego S, Cresta Morgado P, Sole A, Agundez L, Mir G, Castro N, Casals T, Oliveira A, Casanova-Salas I, Malumbres M, Carles J, Morellá-Aucejo Á, Bernardos A, Martínez-Máñez R, Mateo J, Herranz N. Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer. Mol Cancer Ther. 2025 Dec 2;24(12):1959-1976.
  3. Arce-Gallego S, Cresta Morgado P, Delgado-Serrano L, Simonetti S, Gonzalez M, Romero-Lozano P, Marmolejo D, Morales-Barrera R, Arnau GM, Semidey ME, Aguilar D, Cordoba-Terreros S, Mast R, de Albert M, Planas J, Cuadras M, Maldonado X, Suarez C, Casanova-Salas I, Figols M, Cros S, Mas A, Nonell L, Dienstmann R, Nuciforo P, Vivancos A, Llop-Guevara A, Carles J, Serra V, Mateo J. Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence. Cell Rep Med. 2025 Feb 18;6(2):101937.
  4. Gumpert N, Sagie S, Arnedo-Pac C, Babu T, Weller C, Gonzalez-Perez A, Wang Y, Michel Todó L, Levy R, Chen X, Greenberg P, Dayan-Rubinov M, Yakubovich E, Wasserman-Bartov T, Zerbib M, Gong J, Rebernick RJ, Oliveira Tercero A, Agundez Muriel L, Benedek G, Kedmi M, Oren R, Ben-Dor S, Levin Y, Troyanskaya OG, Munzur AD, Wyatt AW, Cieslik MP, Quigley DA, Van Allen EM, Anandasabapathy N, Mateo J, Yang X, Martínez-Jiménez F, Lopez-Bigas N, Samuels Y. Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer. Cancer Discov. 2025. doi: 10.1158/2159-8290.CD-24-1213.
  5. Casanova-Salas I, Aguilar D, Cordoba-Terreros S, Agundez L, Brandariz J, Herranz N, Mas A, Gonzalez M, Morales-Barrera R, Sierra A, Soriano-Navarro M, Cresta P, Mir G, Simonetti S, Rodrigues G, Arce-Gallego S, Delgado-Serrano L, Agustí I, Castellano-Sanz E, Mast R, de Albert M, Celma A, Santamaria A, Gonzalez L, Castro N, Suanes MDM, Hernández-Losa J, Nonell L, Peinado H, Carles J, Mateo J. Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution. Cancer Cell. 2024 Jul 8;42(7):1301-1312.e7.
  6. Garcia-Ruiz A, Macarro C, Zacchi F, Morales-Barrera R, Grussu F, Casanova-Salas I, Sanguedolce F, Gonzalez M, Cresta-Morgado P, de Albert M, Garcia-Bennett J, Marmolejo D, Planas J, Roche S, Mast R, Zatse C, Piulats JM, Herrera-Imbroda B, Regis L, Agundez L, Olmos D, Calvo N, Escobar M, Carles J, Mateo J, Perez-Lopez R. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial. Eur Urol. 2024 Sep;86(3):272-274.
  7. Mateo J, de Bono JS, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Agarwal N, Olmos D, Thiery-Vuillemin A, Özgüroğlu M, Mehra N, Matsubara N, Young Joung J, Padua C, Korbenfeld E, Kang J, Marshall H, Lai Z, Barnicle A, Poehlein C, Lukashchuk N, Hussain M. Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial. J Clin Oncol. 2024 Feb 10;42(5):571-583.
  8. Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, Zohren F, Agarwal N. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med. 2024 Jan;30(1):257-264.

All publications

  1. Arce-Gallego S, Esquefa V, Domenech H, Salca A, Aguilar D, Casals T, Mir G, Simonetti S, Oliveira A, de Llobet L, Neeb A, Brandariz J, Anselmino N, Casanova-Salas I, Herranz N, Serra V, de Bono JS, Mateo J. Combination therapy overcomes secondary PARPi resistance in ATM-deficient prostate cancer. NPJ Precis Oncol. 2025 Nov 26;9(1):407. doi: 10.1038/s41698-025-01179-y. PMID: 41299058; PMCID: PMC12750001.
  2. Grussu F, Grigoriou A, Bernatowicz K, Palombo M, Casanova-Salas I, Navarro-Garcia D, Barba I, Simonetti S, Serna G, Macarro C, Voronova AK, Garay V, Corral JF, Vidorreta M, García-Polo García P, Merino X, Mast R, Rosón N, Escobar M, Vieito M, Toledo R, Nuciforo P, Mateo J, Garralda E, Perez-Lopez R. Clinically feasible liver tumour cell size measurement through histology-informed in vivo diffusion MRI. Commun Med (Lond). 2025 Nov 20;5(1):535. doi: 10.1038/s43856-025-01246-2. PMID: 41266804; PMCID: PMC12749696.
  3. Gumpert N, Sagie S, Arnedo-Pac C, Babu T, Weller C, Gonzalez-Perez A, Wang Y, Michel Todó L, Levy R, Chen X, Greenberg P, Dayan-Rubinov M, Yakubovich E, Wasserman-Bartov T, Zerbib M, Gong J, Rebernick RJ, Oliveira Tercero A, Agundez Muriel L, Benedek G, Kedmi M, Oren R, Ben-Dor S, Levin Y, Troyanskaya OG, Munzur AD, Wyatt AW, Cieslik MP, Quigley DA, Van Allen EM, Anandasabapathy N, Mateo J, Yang X, Martínez-Jiménez F, Lopez-Bigas N, Samuels Y. Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer. Cancer Discov. 2026 Feb 6;16(2):250-269. doi: 10.1158/2159-8290.CD-24-1213. PMID: 41056506; PMCID: PMC12749549.
  4. Bacca L, Brandariz J, Zacchi F, Zivi A, Mateo J, Labbé DP. Therapy-induced senescence in prostate cancer: mechanisms, therapeutic strategies, and clinical implications. Gene. 2025 Nov 20;972:149774. doi: 10.1016/j.gene.2025.149774. Epub 2025 Sep 22. PMID: 40992550.
  5. Sanchis P, Sabater A, Lechuga J, Rada J, Seniuk R, Pascual G, Gatti M, Bizzotto J, Shepherd PDA, Yang J, Cotignola J, Vazquez E, Mateo J, Valacco P, Labanca E, Logothetis C, Gueron G, Anselmino N. PKA-driven SPP1 activation as a novel mechanism connecting the bone microenvironment to prostate cancer progression. Oncogene. 2025 Oct;44(38):3568-3579. doi: 10.1038/s41388-025-03511-z. Epub 2025 Aug 2. PMID: 40753365; PMCID: PMC12436191.
  6. Zurita AJ, Tidwell RS, Chapin BF, Harris DR, Zhang M, Pisters LL, Aparicio A, Araujo JC, Arce-Gallego S, Zhu K, Lozano ML, Pagliaro L, Mateo J, Logothetis C, Troncoso P, Davis JW. Randomized Phase 2 Trial of Presurgical Androgen Deprivation Therapy With or Without Axitinib in Prostate Cancer Presenting With Lymph Node Metastasis. Eur Urol Oncol. 2025 Aug;8(4):1010-1019. doi: 10.1016/j.euo.2025.04.015. Epub 2025 Jul 12. PMID: 40651932.
  7. Brandariz J, de Llobet L, Esquefa V, Aguilar D, Salca A, Arce-Gallego S, Cresta Morgado P, Sole A, Agundez L, Mir G, Castro N, Casals T, Oliveira A, Casanova-Salas I, Malumbres M, Carles J, Morellá-Aucejo Á, Bernardos A, Martínez-Máñez R, Mateo J, Herranz N. Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer. Mol Cancer Ther. 2025 Dec 2;24(12):1959-1976. doi: 10.1158/1535-7163.MCT-24-0903. PMID: 40601842.
  8. Martin-Martin N, Garcia-Longarte S, Corres-Mendizabal J, Lazcano U, Astobiza I, Bozal-Basterra L, Herranz N, van Splunder H, Carlevaris O, Pujana-Vaquerizo M, Blasco MT, Aransay AM, Rosino A, Tudela J, Jimenez D, Martinez A, Salca A, Santos-Martín A, Rey S, Ugalde-Olano A, Gonzalo D, Graupera M, Gomis RR, Mateo J, Unda M, Gonzalez-Billalabeitia E, Loizaga-Iriarte A, Mendizabal I, Carracedo A. Transcriptional analysis of metastatic hormone-naïve prostate cancer primary tumor biopsies reveals a relevant role for SOX11 in prostate cancer cell dissemination. Genome Biol. 2025 Jun 3;26(1):154. doi: 10.1186/s13059-025-03623-5. PMID: 40462200; PMCID: PMC12135548.
  9. Balaguer-Montero M, Marcos Morales A, Ligero M, Zatse C, Leiva D, Atlagich LM, Staikoglou N, Viaplana C, Monreal C, Mateo J, Hernando J, García-Álvarez A, Salvà F, Capdevila J, Elez E, Dienstmann R, Garralda E, Perez-Lopez R. A CT-based deep learning-driven tool for automatic liver tumor detection and delineation in patients with cancer. Cell Rep Med. 2025 Apr 15;6(4):102032. doi: 10.1016/j.xcrm.2025.102032. Epub 2025 Mar 20. PMID: 40118052; PMCID: PMC12047525.
  10. Arce-Gallego S, Cresta Morgado P, Delgado-Serrano L, Simonetti S, Gonzalez M, Romero-Lozano P, Marmolejo D, Morales-Barrera R, Arnau GM, Semidey ME, Aguilar D, Cordoba-Terreros S, Mast R, de Albert M, Planas J, Cuadras M, Maldonado X, Suarez C, Casanova-Salas I, Figols M, Cros S, Mas A, Nonell L, Dienstmann R, Nuciforo P, Vivancos A, Llop-Guevara A, Carles J, Serra V, Mateo J. Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence. Cell Rep Med. 2025 Feb 18;6(2):101937. doi: 10.1016/j.xcrm.2025.101937. Epub 2025 Feb 5. PMID: 39914385; PMCID: PMC11866514.
  11. Naqvi SAA, Riaz IB, Bibi A, Khan MA, Imran M, Khakwani KZR, Raina A, Anjum MU, Cobran EK, Warner JL, Hussain SA, Singh P, Childs DS, Baca SC, Orme JJ, Mateo J, Agarwal N, Gillessen S, Murad MH, Sartor O, Bryce AH. Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis. Eur Urol. 2025 Jun;87(6):626-640. doi: 10.1016/j.eururo.2024.12.007. Epub 2025 Jan 23. PMID: 39848867.
  12. Zacchi F, Abida W, Antonarakis ES, Bryce AH, Castro E, Cheng HH, Shandhu S, Mateo J. Recent and Future Developments in the Use of Poly (ADP-ribose) Polymerase Inhibitors for Prostate Cancer. Eur Urol Oncol. 2025 Jun;8(3):818-828. doi: 10.1016/j.euo.2024.11.011. Epub 2024 Dec 5. PMID: 39638687; PMCID: PMC12797174.
  13. Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Zilli T, Agarwal N, Antonarakis ES, Aparicio A, Armstrong AJ, Bastos DA, Attard G, Axcrona K, Ayadi M, Beltran H, Bjartell A, Blanchard P, Bourlon MT, Briganti A, Bulbul M, Buttigliero C, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Clarke CS, Clarke N, de Bono JS, De Santis M, Duran I, Efstathiou E, Ekeke ON, El Nahas TIH, Emmett L, Fanti S, Fatiregun OA, Feng FY, Fong PCC, Fonteyne V, Fossati N, George DJ, Gleave ME, Gravis G, Halabi S, Heinrich D, Herrmann K, Hofman MS, Hope TA, Horvath LG, Hussain MHA, Jereczek-Fossa BA, Jones RJ, Joshua AM, Kanesvaran R, Keizman D, Khauli RB, Kramer G, Loeb S, Mahal BA, Maluf FC, Mateo J, Matheson D, Matikainen MP, McDermott R, McKay RR, Mehra N, Merseburger AS, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Mutambirwa SBA, Nguyen PL, Oh WK, Ost P, O’Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Renard-Penna R, Ryan CJ, Saad F, Sade JP, Sandhu S, Sartor OA, Schaeffer E, Scher HI, Sharifi N, Skoneczna IA, Soule HR, Spratt DE, Srinivas S, Sternberg CN, Suzuki H, Taplin ME, Thellenberg-Karlsson C, Tilki D, Türkeri LN, Uemura H, Ürün Y, Vale CL, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). Eur Urol. 2025 Feb;87(2):157-216. doi: 10.1016/j.eururo.2024.09.017. Epub 2024 Oct 11. PMID: 39394013.
  14. Francini E, Agarwal N, Castro E, Cheng HH, Chi KN, Clarke N, Mateo J, Rathkopf D, Saad F, Tombal B. Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review. Eur Urol. 2025 Jan;87(1):29-46. doi: 10.1016/j.eururo.2024.09.008. Epub 2024 Sep 20. PMID: 39306478.
  15. Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Szczylik C, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Saad F, Dunshee C, Zschäbitz S, Oldenburg J, Lin X, Healy CG, Kalac M, Kennedy D, Fizazi K. Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet. 2025 Aug 2;406(10502):447-460. doi: 10.1016/S0140-6736(25)00684-1. Epub 2025 Jul 16. PMID: 40683290.
  16. Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Kalac M, Douglas Laird A, Kennedy D, Agarwal N. Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet. 2025 Aug 2;406(10502):461-474. doi: 10.1016/S0140-6736(25)00683-X. Epub 2025 Jul 16. PMID: 40683287.
  18. Fracassi G, Lorenzin F, Orlando F, Gioia U, D’Amato G, Casaramona AS, Cantore T, Prandi D, Santer FR, Klocker H, d’Adda di Fagagna F, Mateo J, Demichelis F. CRISPR/Cas9 screens identify LIG1 as a sensitizer of PARP inhibitors in castration-resistant prostate cancer. J Clin Invest. 2024 Dec 24;135(4):e179393. doi: 10.1172/JCI179393.
  19. Zacchi F, Abida W, Antonarakis ES, Bryce AH, Castro E, Cheng HH, Shandhu S, Mateo J. Recent and Future Developments in the Use of Poly (ADP-ribose) Polymerase Inhibitors for Prostate Cancer. Eur Urol Oncol. 2024 Dec 4:S2588-9311(24)00273-6. doi: 10.1016/j.euo.2024.11.011. Epub ahead of print.
  20. Seed G, Beije N, Yuan W, Bertan C, Goodall J, Lundberg A, Tyler M, Figueiredo I, Pereira R, Baker C, Bogdan D, Gallagher L, Cieslik JP, Greening S, Lambros M, Neves R, Magraner-Pardo L, Fowler G, Ebbs B, Miranda S, Flohr P, Bianchini D, Rescigno P, Porta N, Hall E, Gurel B, Tunariu N, Sharp A, Pettit S, Stoecklein NH, Sandhu S, Quigley D, Lord CJ, Mateo J, Carreira S, de Bono J. Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. Cancer Cell. 2024 Dec 9;42(12):2113-2123.e4. doi: 10.1016/j.ccell.2024.10.015.
  21. Seed G, Beije N, Yuan W, Bertan C, Goodall J, Lundberg A, Tyler M, Figueiredo I, Pereira R, Baker C, Bogdan D, Gallagher L, Cieslik JP, Greening S, Lambros M, Neves R, Magraner-Pardo L, Fowler G, Ebbs B, Miranda S, Flohr P, Bianchini D, Rescigno P, Porta N, Hall E, Gurel B, Tunariu N, Sharp A, Pettit S, Stoecklein NH, Sandhu S, Quigley D, Lord CJ, Mateo J, Carreira S, de Bono J. Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. Cancer Cell. 2024 Dec 9;42(12):2113-2123.e4. doi: 10.1016/j.ccell.2024.10.015.
  22. Protasoni M, López-Polo V, Stephan-Otto Attolini C, Brandariz J, Herranz N, Mateo J, Ruiz S, Fernandez-Capetillo O, Kovatcheva M, Serrano M. Cyclophilin D plays a critical role in the survival of senescent cells. EMBO J. 2024 Dec;43(23):5972-6000. doi: 10.1038/s44318-024-00259-2.
  23. Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Zilli T, Agarwal N, Antonarakis ES, Aparicio A, Armstrong AJ, Bastos DA, Attard G, Axcrona K, Ayadi M, Beltran H, Bjartell A, Blanchard P, Bourlon MT, Briganti A, Bulbul M, Buttigliero C, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Clarke CS, Clarke N, de Bono JS, De Santis M, Duran I, Efstathiou E, Ekeke ON, El Nahas TIH, Emmett L, Fanti S, Fatiregun OA, Feng FY, Fong PCC, Fonteyne V, Fossati N, George DJ, Gleave ME, Gravis G, Halabi S, Heinrich D, Herrmann K, Hofman MS, Hope TA, Horvath LG, Hussain MHA, Jereczek-Fossa BA, Jones RJ, Joshua AM, Kanesvaran R, Keizman D, Khauli RB, Kramer G, Loeb S, Mahal BA, Maluf FC, Mateo J, Matheson D, Matikainen MP, McDermott R, McKay RR, Mehra N, Merseburger AS, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Mutambirwa SBA, Nguyen PL, Oh WK, Ost P, O’Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Renard-Penna R, Ryan CJ, Saad F, Sade JP, Sandhu S, Sartor OA, Schaeffer E, Scher HI, Sharifi N, Skoneczna IA, Soule HR, Spratt DE, Srinivas S, Sternberg CN, Suzuki H, Taplin ME, Thellenberg-Karlsson C, Tilki D, Türkeri LN, Uemura H, Ürün Y, Vale CL, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). Eur Urol. 2025 Feb;87(2):157-216. doi: 10.1016/j.eururo.2024.09.017. Epub 2024 Oct 11.
  24. Francini E, Agarwal N, Castro E, Cheng HH, Chi KN, Clarke N, Mateo J, Rathkopf D, Saad F, Tombal B. Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review. Eur Urol. 2025 Jan;87(1):29-46. doi: 10.1016/j.eururo.2024.09.008. Epub 2024 Sep 20.
  25. Mateo J, Zurita AJ. 177Lu-PSMA-617 for metastatic prostate cancer: aiming for the right spot. Lancet. 2024 Sep 28;404(10459):1174-1176. doi: 10.1016/S0140-6736(24)01919-6.
  26. Corres-Mendizabal J, Zacchi F, Martín-Martín N, Mateo J, Carracedo A. Metastatic hormone-naïve prostate cancer: a distinct biological entity. Trends Cancer. 2024 Sep;10(9):825-841. doi: 10.1016/j.trecan.2024.06.005.
  27. Casanova-Salas I, Aguilar D, Cordoba-Terreros S, Agundez L, Brandariz J, Herranz N, Mas A, Gonzalez M, Morales-Barrera R, Sierra A, Soriano-Navarro M, Cresta P, Mir G, Simonetti S, Rodrigues G, Arce-Gallego S, Delgado-Serrano L, Agustí I, Castellano-Sanz E, Mast R, de Albert M, Celma A, Santamaria A, Gonzalez L, Castro N, Suanes MDM, Hernández-Losa J, Nonell L, Peinado H, Carles J, Mateo J. Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution. Cancer Cell. 2024 Jul 8;42(7):1301-1312.e7. doi: 10.1016/j.ccell.2024.06.003.
  28. Carmichael J, Figueiredo I, Gurel B, Beije N, Yuan W, Rekowski J, Seed G, Carreira S, Bertan C, Fenor de La Maza MLD, Chandran K, Neeb A, Welti J, Gallagher L, Bogdan D, Crespo M, Riisnaes R, Ferreira A, Miranda S, Lu J, Shen MM, Hall E, Porta N, Westaby D, Guo C, Grochot R, Lord CJ, Mateo J, Sharp A, de Bono J. RNASEH2B loss and PARP inhibition in advanced prostate cancer. J Clin Invest. 2024 Jun 4;134(21):e178278. doi: 10.1172/JCI178278.
  29. Zacchi F, Carles J, Gonzalez M, Maldonado X, Perez-Lopez R, Semidey ME, Mateo J. Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient. Front Oncol. 2024 Mar 8;14:1331643. doi: 10.3389/fonc.2024.1331643.
  30. Garcia-Ruiz A, Macarro C, Zacchi F, Morales-Barrera R, Grussu F, Casanova-Salas I, Sanguedolce F, Gonzalez M, Cresta-Morgado P, de Albert M, Garcia-Bennett J, Marmolejo D, Planas J, Roche S, Mast R, Zatse C, Piulats JM, Herrera-Imbroda B, Regis L, Agundez L, Olmos D, Calvo N, Escobar M, Carles J, Mateo J, Perez-Lopez R. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial. Eur Urol. 2024 Sep;86(3):272-274. doi: 10.1016/j.eururo.2024.02.016.
  31. Chen N, McGrath CB, Ericsson CI, Vaselkiv JB, Rencsok EM, Stopsack KH, Guard HE, Autio KA, Rathkopf DE, Enting D, Bitting RL, Mateo J, Githiaka CW, Chi KN, Cheng HH, Davis ID, Anderson SG, Badal SAM, Bjartell A, Russnes KM, Heath EI, Pomerantz MM, Henegan JC, Hyslop T, Esteban E, Omlin A, McDermott R, Fay AP, Popoola AA, Ragin C, Nowak J, Gerke T, Kantoff PW, George DJ, Penney KL, Mucci LA; IRONMAN Registry. Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2024 Mar 1;33(3):419-425. doi: 10.1158/1055-9965.EPI-23-1207.
  32. Mateo J, de Bono JS, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Agarwal N, Olmos D, Thiery-Vuillemin A, Özgüroğlu M, Mehra N, Matsubara N, Young Joung J, Padua C, Korbenfeld E, Kang J, Marshall H, Lai Z, Barnicle A, Poehlein C, Lukashchuk N, Hussain M. Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial. J Clin Oncol. 2024 Feb 10;42(5):571-583. doi: 10.1200/JCO.23.00339.
  33. Shore N, Carles J, McDermott R, Agarwal N, Tombal B. Treatment intensification with radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer. Front Med (Lausanne). 2024 Oct 24;11:1460212. doi: 10.3389/fmed.2024.1460212.
  34. Azad AA, Fizazi K, Matsubara N, Saad F, De Giorgi U, Joung JY, Fong PCC, Jones RJ, Zschäbitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Fay AP, Lin X, DeAnnuntis L, Di Santo N, Zielinski MA, Agarwal N. Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study. Eur J Cancer. 2024 Dec;213:115078. doi: 10.1016/j.ejca.2024.115078.
  35. Jiménez N, Garcia de Herreros M, Reig Ò, Marín-Aguilera M, Aversa C, Ferrer-Mileo L, García-Esteve S, Rodríguez-Carunchio L, Trias I, Font A, Rodriguez-Vida A, Climent MÁ, Cros S, Chirivella I, Domènech M, Figols M, Carles J, Suárez C, Herrero Rivera D, González-Billalabeitia E, Cívico C, Sala-González N, Ruiz de Porras V, Ribal MJ, Prat A, Mellado B. Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients. Eur Urol Oncol. 2024 Aug;7(4):954-964. doi: 10.1016/j.euo.2023.12.012.
  36. Shore ND, Gratzke C, Feyerabend S, Werbrouck P, Carles J, Vjaters E, Tammela TLJ, Morris D, Aragon-Ching JB, Concepcion RS, Emmenegger U, Fleshner N, Grabbert M, Lietuvietis V, Mahammedi H, Cruz FM, Paula A, Pieczonka C, Rannikko A, Richardet M, Silveira G, Kuss I, Le Berre MA, Verholen F, Sarapohja T, Smith MR, Fizazi K. Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS. Oncologist. 2024 Jul 5;29(7):581-588. doi: 10.1093/oncolo/oyae019.
  37. Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, Zohren F, Agarwal N. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med. 2024 Jan;30(1):257-264. doi: 10.1038/s41591-023-02704-x. Epub 2023 Dec 4. Erratum in: Nat Med. 2024 May;30(5):1505. doi: 10.1038/s41591-024-02835-9.
  38. Mateo J, de Bono JS, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Agarwal N, Olmos D, Thiery-Vuillemin A, Özgüroğlu M, Mehra N, Matsubara N, Young Joung J, Padua C, Korbenfeld E, Kang J, Marshall H, Lai Z, Barnicle A, Poehlein C, Lukashchuk N, Hussain M. Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial. J Clin Oncol. 2023 Nov 14:JCO2300339. doi: 10.1200/JCO.23.00339. Epub ahead of print. PMID: 37963304.
  39.  Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O’Sullivan JM, Padhani AR, Pezaro CJ, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer. 2023 May;185:178-215. doi: 10.1016/j.ejca.2023.02.018. Epub 2023 Mar 3. PMID: 37003085.
  40.  Chi KN, Barnicle A, Sibilla C, Lai Z, Corcoran C, Barrett JC, Adelman CA, Qiu P, Easter A, Dearden S, Oxnard GR, Agarwal N, Azad A, de Bono J, Mateo J, Olmos D, Thiery-Vuillemin A, Harrington EA. Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound. Clin Cancer Res. 2023 Jan 4;29(1):81-91. doi: 10.1158/1078-0432.CCR-22-0931. PMID: 36043882; PMCID: PMC9811161.
  41.  Mateo J, Beltran H. Moving Precision Oncology for Advanced Prostate Cancer from Theory to Practice. Eur Urol Focus. 2023 Jan;9(1):110-113. doi: 10.1016/j.euf.2022.08.004. Epub 2022 Aug 20. PMID: 35999168.
  42.  Schostak M, Bradbury A, Briganti A, Gonzalez D, Gomella L, Mateo J, Penault-Llorca F, Stenzinger A, Wyatt AW, Bjartell A. Practical Guidance on Establishing a Molecular Testing Pathway for Alterations in Homologous Recombination Repair Genes in Clinical Practice for Patients with Metastatic Prostate Cancer. Eur Urol Oncol. 2023 Sep 13:S2588-9311(23)00166-9. doi: 10.1016/j.euo.2023.08.004. Epub ahead of print. PMID: 37714762.
  43.  Turpin A, Delliaux C, Parent P, Chevalier H, Escudero-Iriarte C, Bonardi F, Vanpouille N, Flourens A, Querol J, Carnot A, Leroy X, Herranz N, Lanel T, Villers A, Olivier J, Touzet H, de Launoit Y, Tian TV, Duterque-Coquillaud M. Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor. Br J Cancer. 2023 Dec;129(12):1903-1914. doi: 10.1038/s41416-023-02449-x. Epub 2023 Oct 24. PMID: 37875732; PMCID: PMC10703930.
  44.  Grochot R, Carreira S, Miranda S, Figueiredo I, Bertan C, Rekowski J, Yuan W, Ferreira A, Riisnaes R, Neeb A, Gurel B, de Los Dolores Fenor de la Maza M, Guo C, Carmichael J, Westaby D, Mateo J, Sharp A, McVeigh TP, De Bono J. Germline ATM Mutations Detected by Somatic DNA Sequencing in Lethal Prostate Cancer. Eur Urol Open Sci. 2023 May 2;52:72-78. doi: 10.1016/j.euros.2023.04.003. PMID: 37284046; PMCID: PMC10240520.
  45.  Beije N, Abida W, Antonarakis ES, Castro E, de Wit R, Fizazi K, Gillessen S, Hussain M, Mateo J, Morris MJ, Olmos D, Sartor O, Sharp A, Sweeney CJ, de Bono JS. PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues. Eur Urol. 2023 Sep;84(3):253-256. doi: 10.1016/j.eururo.2023.03.038. Epub 2023 Apr 20. PMID: 37087376.
  46.  Lozano R, Castro E, Lopez-Campos F, Thorne H, Ramirez-Backhaus M, Aragon IM, Cendón-Florez Y, Gutierrez-Pecharroman A, Salles DC, Romero-Laorden N, Lorente D, González-Peramato P, Calatrava A, Alonso C, Anido U, Arévalo-Lobera S, Balmaña J, Chirivella I, Juan-Fita MJ, Llort G, Y Cajal TR, Almagro E, Alameda D, López-Casas PP, Herrera B, Mateo J, Pritchard CC, Antonarakis ES, Lotan TL, Rubio-Briones J, Sandhu S, Olmos D. Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers. Eur J Cancer. 2023 May;185:105-118. doi: 10.1016/j.ejca.2023.02.022. Epub 2023 Mar 5. PMID: 36972661.
  47.  Casolino R, Johns AL, Courtot M, Lawlor RT, De Lorenzo F, Horgan D, Mateo J, Normanno N, Rubin M, Stein L, Subbiah V, Westphalen BC, Lawler M, Park K, Perdomo S, Yoshino T, Wu J, Biankin AV; Lancet Oncology Commission on Cancer Omics and Precision Oncology. Accelerating cancer omics and precision oncology in health care and research: a Lancet Oncology Commission. Lancet Oncol. 2023 Feb;24(2):123-125. doi: 10.1016/S1470-2045(23)00007-4. PMID: 36725142.
  48. Casanova-Salas I, Aguilar D, Cordoba-Terreros S, Agundez L, Brandariz J, Herranz N, Mas A, Gonzalez M, Morales-Barrera R, Sierra A, Soriano-Navarro M, Cresta P, Mir G, Simonetti S, Rodrigues G, Arce-Gallego S, Delgado-Serrano L, Agustí I, Castellano-Sanz E, Mast R, de Albert M, Celma A, Santamaria A, Gonzalez L, Castro N, Suanes MDM, Hernández-Losa J, Nonell L, Peinado H, Carles J, Mateo J. Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution. Cancer Cell. 2024 Jul 8;42(7):1301-1312.e7. doi: 10.1016/j.ccell.2024.06.003. PMID: 38981440.
  49. Garcia-Ruiz A, Macarro C, Zacchi F, Morales-Barrera R, Grussu F, Casanova-Salas I, Sanguedolce F, Gonzalez M, Cresta-Morgado P, de Albert M, Garcia-Bennett J, Marmolejo D, Planas J, Roche S, Mast R, Zatse C, Piulats JM, Herrera-Imbroda B, Regis L, Agundez L, Olmos D, Calvo N, Escobar M, Carles J, Mateo J, Perez-Lopez R. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial. Eur Urol. 2024 Sep;86(3):272-274. doi: 10.1016/j.eururo.2024.02.016. Epub 2024 Mar 14. PMID: 38490857.
  50. Mateo J, de Bono JS, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Agarwal N, Olmos D, Thiery-Vuillemin A, Özgüroğlu M, Mehra N, Matsubara N, Young Joung J, Padua C, Korbenfeld E, Kang J, Marshall H, Lai Z, Barnicle A, Poehlein C, Lukashchuk N, Hussain M. Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial. J Clin Oncol. 2024 Feb 10;42(5):571-583. doi: 10.1200/JCO.23.00339. Epub 2023 Nov 14. PMID: 37963304.
  51. Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, Zohren F, Agarwal N. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med. 2024 Jan;30(1):257-264. doi: 10.1038/s41591-023-02704-x. Epub 2023 Dec 4. Erratum in: Nat Med. 2024 May;30(5):1505. doi: 10.1038/s41591-024-02835-9. PMID: 38049622; PMCID: PMC10803259.

Projects

  • A deep learning framework to predict BRCA mutations from digital pathology slides. PI: Joaquin Mateo and Raquel Perez-Lopez. Grantor: AstraZeneca and ISC-III Duration: 2025-2026
  • Computational modelling of tumour evolution and treatment resistance in prostate cancer. PI: Richard Norris. Grantor: Fundacion AECC Duration: 2025-2028
  • ctDNA profiling in metastatic prostate cancer. Grantor: Guardant Health. PI: Joaquin Mateo. Duration: 2024-2025.
  • Targeting Resistance: Mechanisms and Modulators of PARP Inhibitor Response in Prostate Cancer. PI: Nicolas Anselmino. Grantor: Fundación AECC. Duration: 2024-2027.
  • Dissecting mechanisms of resistance and the interaction between PARPi use and AR in men with prostate cancer. PI: Joaquin Mateo. Grantor: AstraZeneca. Duration: 2024-2026.
  • A novel liquid biopsy assay using circulating tumor extracellular vesicles to monitor prostate cancer tumor evolution and emergence of drug resistance. PI: Irene Casanova.Funded by:Prostate Cancer Foundation (PCF).Duration: 2024-2027
  • Development of NT1, a potent and selective best-in-class drug targeting the Androgen Receptor disordered domain for the treatment of Castration Resistant Prostate Cancer. PI: Joaquin Mateo. Grantor: Programa RETOS Colaboracion Publico-Privada, Spanish Ministry of Science. Duration: 2024-2026.
  • Multimodal Biomarkers for Precise Management of Metastatic Prostate Cancer. Co-PIs: Joaquin Mateo and Raquel Perez Lopez.
    Grantor: Programa RETOS Colaboracion Publico-Privada, Spanish Ministry of Science. Duration: 2023-2025.
  • Impact of hormonal therapy-induced senescence in the immune-tumor interaction in prostate cancer. PI: Nicolas Herranz. Grantor: Spanish Ministry of Health, FIS Program. Duration: 2024-2026.
  • Studying intra-tumor heterogeneity in the evolution of metastatic hormone-naïve prostate cancer to castration-resistance after intensified hormonal therapy. PI: Joaquin Mateo. Grantor: Department of Defense CDMRP (United States) 2022 Call. Duration: 2023-2026.
  • Clinical Qualification of DNA Repair Defects as Biomarkers in Metastatic Prostate Cancer Using Integrated Genomics and Tissue-Based Functional Assays. PI: Joaquin Mateo. Grantor: US Department of Defense Congressionally-Directed Medical Research Program. Duration: 2018-2023.
  • Leveraging the AR-DDR interaction in de-novo metastatic prostate cancer towards precision combination therapies with PARP inhibitors. PI: Joaquin Mateo. Grantor: AECC (Fundación Asociación Española contra el Cáncer). Duration: 2020-2023.
  • Integrated analysis of blood circulating tumor signatures to monitor genomic evolution and therapy responses in advanced Prostate Cancer. PI: Irene Casanova-Salas Grantor: ”la Caixa” Foundation. Duration: 2021-2024.
  • Exploiting senescence in a two-step approach to treat advanced Prostate Cancer. PI: Nicolas Herranz. Grantor: Instituto de Salud Carlos III (ISCIII). Duration: 2021-2023.
  • Tumoral senescence induced by anti-cancer therapies constitutes a novel prognostic biomarker and a therapeutic target. Co-PIs: Manuel Serrano, Maria Abad, Raquel Perez and Joaquin Mateo. Grantor: AECC (Fundación Asociación Española contra el Cáncer). Duration: 2022-2026.
  • Prostate Cancer Genomic Evolution and Signatures of DNA Damage Repair Deficiencies. PI: Joaquin Mateo. Grantor: CRIS Cancer Foundation. Duration: 2021-2025.

Related News

Lab VHIO 2025
Landmark global initiative sets out a new roadmap for equitable precision oncology

  An international team of scientists has launched a global roadmap for the delivery of advanced cancer treatments, paving the…

25 Sep 2026
Padel Movember will support a research project to understand the mechanisms of resistance in prostate cancer treatment

On 10 June, the organizers of the Padel Movember tournament visited the VHIO facilities to present the cheque for €5.601…

20 Jun 2025
Three VHIO Researchers Awarded PERIS Grants to Strengthen Their Research Activity

The Department of Health of the Government of Catalonia has awarded 36 grants to intensify research activity among health science…

25 Feb 2026
Clinically qualifying predictive biomarkers of response to PARPi in patients with prostate cancer

PARP inhibitors (PARPi) are approved for treating advanced prostate cancers with various defective DNA repair genes, although not all patients…

26 Aug 2021
Diagnostic tissue biopsy: informing biomarker-driven clinical decision making in advanced prostate cancer

Results of a VHIO co-led retrospective study published in JCO Precision Oncology verify the use of diagnostic archival tissue biopsies…

13 Jul 2022
Dr. Joaquin Mateo y Dra. Irene Casanova en el laboratorio
Novel liquid biopsy methodology enables the monitoring of disease evolution in patients with metastatic prostate cancer

Extracellular vesicles shed by prostate cancer cells to the bloodstream contain tumor-derived material that can be used as biomarkers of…

08 Jul 2024
Joaquin Mateo bata VHIO 2026
VHIO presents new advances at ASCO consolidating precision medicine in metastatic prostate cancer

Results from the phase 3 TALAPRO-3 trial show that the combination of enzalutamide and talazoparib reduces the risk of progression…

30 May 2026
Joaquin Mateo: a duo of expert ecancer talks on Genomics in Oncology

The oncology channel ecancer recently launched a new series of videos focused on Genomics in Oncology. Leading experts are invited…

02 Nov 2022
RAD51 biomarker could complement next-generation sequencing in personalizing prostate cancer treatment

Published in Cell Reports Medicine*, results of a VHIO-led study support the feasibility of using RAD51 testing to complement next-generation…

05 Feb 2025
Precision medicine improves survival outcomes for patients with metastatic castration-resistant prostate cancer with BRCA gene alterations

Approximately 10% of patients with metastatic castration-resistant prostate cancer have alterations in the BRCA1 or BRCA2 genes which are associated…

14 Nov 2023
Joaquin Mateo - Joan Carles VHIO
A study led by SOLTI and VHIO facilitates nationwide access to genomic testing across Spain for patients with metastatic prostate cancer and redefines therapeutic strategy in more than half of cases

The HOPE Prostate (SOLTI-2102) study analyzed 208 samples (116 tissue and 92 liquid biopsies) from 146 patients with metastatic prostate…

14 Nov 2025
iPROMET: whole-body magnetic imaging as a biomarker of treatment response in prostate cancer with bone metastases

Results of the multi-center iPROMET study identify whole-body magnetic resonance imaging as a biomarker of response in prostate cancer patients…

04 Apr 2024
Julian Brandariz Joaquin Mateo VHIO 2025
Novel one-two punch treatment strategy shows promise in preclinical models of advanced prostate cancer

Results of a study led by VHIO’s Prostate Cancer Group suggest that treatment with CDK4/6 inhibitors followed by senloytic therapies…

22 Jul 2025
Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.
Privacy Policy
You have read and agreed to our privacy policy
Required